SEC Tracker
Get the app

Karyopharm Therapeutics KPTI

Karyopharm extends forbearance period

Form
8-K
Filed
Importance
Routine
  1. Forbearance period extended to Oct 22, 2026
  2. Original end date was Oct 15, 2026
  3. Forbearance Agreement dated Sep 10, 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Karyopharm Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  2. BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
  3. Annovis Bio ANVS public float $36M, Jun 30, 2025
  4. Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025
  5. Grace Therapeutics GRCE public float $35M, Sep 30, 2025